{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-148114","form_type":"8-K","ticker":"HOWL","cik":"0001785530","company_name":"Werewolf Therapeutics, Inc.","filed_at":"2024-05-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.101637+00:00","generated_at":"2026-06-01T08:09:06.033798+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Werewolf Therapeutics shareholders elect three Class III directors, ratify EY auditor","bullets":["Elected Michael Atkins, Luke Evnin, and Alon Lazarus as Class III directors; Atkins 31.6M votes for, Evnin 20.7M, Lazarus 31.5M.","Broker non-votes of 5.1M shares on each director election.","Ratified Ernst & Young as independent auditor for FY2024: 36.7M for, 41.9K against, 2.9K abstain."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-148114","json":"https://secwatch.observer/filing/0001193125-24-148114.json","markdown":"https://secwatch.observer/filing/0001193125-24-148114.md","text":"https://secwatch.observer/filing/0001193125-24-148114.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785530/000119312524148114/0001193125-24-148114-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785530/000119312524148114/d794252d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T08:09:06.033798+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}